Acta Neurol Belg (2017) 117:753–755 DOI 10.1007/s13760-017-0751-5 LETTER TO THE EDITOR Intravenous thrombolysis after reversal of dabigatran by idarucizumab: a moment to be a pioneer 1 1 2 3 4 • • • • G. Turine A. Peeters C. Hermans S. Eeckhoudt T. Duprez Received: 18 November 2016 / Accepted: 17 January 2017 / Published online: 30 January 2017 Belgian Neurological Society 2017 Keywords Ischemic stroke Intravenous thrombolysis dabigatran 110 mg, which he immediately gave her. At Dabigatran Idarucizumab 5.00 AM, he observed a right facial palsy. As symptoms did not resolve spontaneously, he called the emergency medical service. On admission, blood pressure was Introduction 170/100 mmHg, glycemia was 176 mg/dL, and cardiac rate was 98, irregular. Neurological examination showed Effective anticoagulation is a contraindication for intra- drowsiness, a right-sided paresis of face, arm, and leg, venous thrombolysis (IVT) with recombinant tissue plas- together with right-sided homonymous hemianopsia and minogen activator (rt-PA). We here report our ﬁrst and severe aphasia. The total NIHSS score was 17. successful experience of systemic thrombolysis a few Brain computed tomography (CT) excluded an minutes after reversal of dabigatran by idarucizumab. intracranial hemorrhage and demonstrated an insular and left frontal acute
Acta Neurologica Belgica – Springer Journals
Published: Jan 30, 2017
It’s your single place to instantly
discover and read the research
that matters to you.
Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.
All for just $49/month
Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly
Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.
All the latest content is available, no embargo periods.
“Whoa! It’s like Spotify but for academic articles.”@Phil_Robichaud